ABUS - Arbutus Reports Positive Hepatitis B Data And Other News: The Good Bad And Ugly Of Biopharma
- Arbutus reports positive data for AB-729 for chronic hepatitis B.
- Marinus Pharmaceuticals hits primary endpoint in the Genetic Epilepsy trial.
- Novus Therapeutics on upswing on Anelixis acquisition.
For further details see:
Arbutus Reports Positive Hepatitis B Data, And Other News: The Good, Bad And Ugly Of Biopharma